Needham & Company LLC Reiterates “Hold” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research note issued on Tuesday, Benzinga reports.

Separately, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a report on Monday, April 15th.

Lexicon Pharmaceuticals Trading Down 0.6 %

Shares of LXRX opened at $1.60 on Tuesday. Lexicon Pharmaceuticals has a 1-year low of $0.92 and a 1-year high of $3.79. The company has a 50-day moving average of $2.28 and a 200 day moving average of $1.72. The firm has a market capitalization of $393.98 million, a price-to-earnings ratio of -2.00 and a beta of 1.27. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. On average, research analysts expect that Lexicon Pharmaceuticals will post -0.71 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently made changes to their positions in the business. BVF Inc. IL lifted its stake in shares of Lexicon Pharmaceuticals by 22.2% in the 4th quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after purchasing an additional 4,440,300 shares during the period. SG Americas Securities LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $64,000. KWB Wealth acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $62,000. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $49,000. Finally, TIAA Trust National Association acquired a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $29,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.